Therapeutic implication of molecular profiling in patients with non – small cell lung cancer (original) (raw)

Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study

carlos barrios

2011

View PDFchevron_right

The role of the molecular footprint of EGFR in tailoring treatment decisions in NSCLC: Figure 1

Kathy Gately

Journal of Clinical Pathology, 2011

View PDFchevron_right

Target therapy in NSCLC patients: Relevant clinical agents and tumour molecular characterisation (Review)

Laura Capelli, Paola Ulivi

Molecular and Clinical Oncology, 2013

View PDFchevron_right

A Systematic Review and Canadian Consensus Recommendations on the Use of Biomarkers in the Treatment of Non-small Cell Lung Cancer

Frances Shepherd

Journal of Thoracic Oncology, 2011

View PDFchevron_right

Current Status of Targeted Therapy in Non Small Cell Lung Cancer (NSCLC)

Dinah Parums

View PDFchevron_right

The role of molecular analyses in the era of personalized therapy for advanced NSCLC

Nicholas Pastis

Lung Cancer, 2012

View PDFchevron_right

Genotyping and Genomic Profiling of Non–Small-Cell Lung Cancer: Implications for Current and Future Therapies

Tianhong Li

Journal of Clinical Oncology, 2013

View PDFchevron_right

Diagnostic, Predictive and Prognostic Biomarkers in Non-Small Cell Lung Cancer (NSCLC) Management

Jelena Knežević

Journal of Personalized Medicine

View PDFchevron_right

Molecular Targeted Drugs and Biomarkers in NSCLC, the Evolving Role of Individualized Therapy

Kelly Domvri, Lutz Freitag

Journal of Cancer, 2013

View PDFchevron_right

Influence of polymorphisms on EGFR targeted therapy in non-small-cell lung cancer

Leticia G. León

Frontiers in Bioscience, 2011

View PDFchevron_right

Evaluation of molecular prognostic and predictive factors: an important step towards personalised treatment in non small cell lung cancer

Raffaele Ardito, Alfredo Tartarone

Medical Oncology, 2011

View PDFchevron_right

Non-small cell lung cancer - Genetic predictors

Jiri Drabek, Radek Trojanec

2013

View PDFchevron_right

Oncogenic Pathways, Molecularly Targeted Therapies, and Highlighted Clinical Trials in Non–Small-Cell Lung Cancer (NSCLC)

Saravut Weroha, Thanyanan Reungwetwattana

Clinical Lung Cancer, 2012

View PDFchevron_right

Determinants of Survival in Advanced Non–Small-Cell Lung Cancer in the Era of Targeted Therapies

Tracey Evans

Clinical Lung Cancer, 2013

View PDFchevron_right

Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02)

Mao Mao

Oncotarget, 2016

View PDFchevron_right

EGFR testing and clinical management of advanced NSCLC: a Galician Lung Cancer Group study (GGCP 048-10)

lucia santome

Cancer Management and Research, 2016

View PDFchevron_right

Combined assessment of EGFR pathway-related molecular markers and prognosis of NSCLC patients

Jose Rodriguez

2009

View PDFchevron_right

Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small-Cell Lung Cancer (NSCLC)

Kenneth O'Byrne

Pharmaceuticals, 2020

View PDFchevron_right

Non-small cell lung cancer: the era of targeted therapy

Mara Antonoff

Lung Cancer: Targets and Therapy, 2012

View PDFchevron_right

Other novel molecular targets in non-small cell lung cancer: it’s not all about EGFR

Brett Hughes

View PDFchevron_right

Biomarkers of clinical benefit for anti-epidermal growth factor receptor agents in patients with non-small-cell lung cancer

Athanasios Pallis

British journal of cancer, 2011

View PDFchevron_right

Molecular pathology of lung cancer: key to personalized medicine

Antonio Lopez-beltran

Modern Pathology, 2012

View PDFchevron_right

Predictive and prognostic markers for epidermal growth factor receptor inhibitor therapy in non-small cell lung cancer

Nir Peled

Therapeutic advances in medical oncology, 2009

View PDFchevron_right

Advances towards the design and development of personalized non-small-cell lung cancer drug therapy

Anais Del Curatolo, Ursula C cesta Incani, Italia Falcone

Expert Opinion on Drug Discovery, 2013

View PDFchevron_right

Overall Survival Analysis and Characterization of an EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) Population

Venceslau Hespanhol

Archivos de bronconeumologia, 2017

View PDFchevron_right